Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity - PubMed (original) (raw)

Affiliations

PMID: 9034987

Comparative Study

Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity

C Gabay et al. J Rheumatol. 1997 Feb.

Abstract

Objective: To investigate the difference in acute phase protein responses between patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and spondyloarthropathies (SpA).

Methods: Circulating levels of cytokines inducing the production of acute phase proteins such as interleukin (IL)-6, IL-1 beta, and tumor necrosis factor (TNF)-alpha, and of cytokine inhibitors such as TNF soluble receptors (TNF-sR55 and TNF-sR75) and IL-1 receptor antagonist (IL-1ra), were measured in 2 cohorts of patients. The first cohort included 52 patients with SLE and 22 with RA, and the second included 21 with SLE, 20 with RA, and 18 with SpA. An examination at the time of blood collection and the Systemic Lupus Activity Measure (SLAM) index were used to assess disease activity in patients with SLE. Serum levels of IL-6 were measured using a biological assay, and concentrations of IL-1 beta, TNF-alpha, TNF-sR55, TNF-sR75, and IL-1ra were assessed by immunoassays.

Results: Although C-reactive protein (CRP) levels were significantly lower in SLE than in RA or SpA, the concentrations of circulating IL-6 or TNF-alpha were higher in SLE. The most striking observation was that TNF-sR levels were significantly higher in SLE than in RA or SpA. The TNF-alpha: TNF-sR ratio was also significantly lower in SLE than in RA. TNF-sR55 and TNF-sR75 levels correlated with disease activity in SLE.

Conclusion: The weak acute phase protein response in SLE may be explained by a decreased ratio between inducing cytokines and their inhibitors. In addition, TNF-sR may prove a useful biological marker for the followup of SLE, where acute phase protein response is generally low during disease exacerbations.

PubMed Disclaimer

Cited by

Anti-C1q autoantibodies from systemic lupus erythematosus patients enhance CD40-CD154-mediated inflammation in peripheral blood mononuclear cells in vitro.
Rabatscher PA, Trendelenburg M. Rabatscher PA, et al. Clin Transl Immunology. 2022 Aug 2;11(8):e1408. doi: 10.1002/cti2.1408. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35928801 Free PMC article.
Autoinflammation: From monogenic syndromes to common skin diseases.
Nguyen TV, Cowen EW, Leslie KS. Nguyen TV, et al. J Am Acad Dermatol. 2013 May;68(5):834-53. doi: 10.1016/j.jaad.2012.11.002. Epub 2013 Feb 28. J Am Acad Dermatol. 2013. PMID: 23453357 Free PMC article. Review.
Using Multiple Analytical Platforms to Investigate the Androgen Depletion Effects on Fecal Metabolites in a Mouse Model of Systemic Lupus Erythematosus.
Yuan F, Harder J, Ma J, Yin X, Zhang X, Kosiewicz MM. Yuan F, et al. J Proteome Res. 2020 Feb 7;19(2):667-676. doi: 10.1021/acs.jproteome.9b00558. Epub 2019 Dec 27. J Proteome Res. 2020. PMID: 31820642 Free PMC article.
Cytokines and systemic lupus erythematosus.
Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Dean GS, et al. Ann Rheum Dis. 2000 Apr;59(4):243-51. doi: 10.1136/ard.59.4.243. Ann Rheum Dis. 2000. PMID: 10733469 Free PMC article. Review. No abstract available.
Cytokine disturbances in systemic lupus erythematosus.
Jacob N, Stohl W. Jacob N, et al. Arthritis Res Ther. 2011 Jul 6;13(4):228. doi: 10.1186/ar3349. Arthritis Res Ther. 2011. PMID: 21745419 Free PMC article. Review.

Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity - PubMed (original) (raw)